Shopping Cart
- Remove All
Your shopping cart is currently empty
Motixafortide TFA(664334-36-5,Free)
Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
Catalog No. T14665L
Select Batch
Purity:100%
Contact us for more batch information
Motixafortide TFA(664334-36-5,Free)
Catalog No. T14665LAlias TF 14016 TFA, T140 TFA, BL-8040 TFA, BKT140 TFA
Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $68 | In Stock | |
| 5 mg | $198 | In Stock | |
| 10 mg | $297 | In Stock | |
| 25 mg | $475 | In Stock | |
| 50 mg | $672 | In Stock | |
| 100 mg | $893 | In Stock | |
| 200 mg | $1,180 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Motixafortide TFA(664334-36-5,Free)"
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Tannic acid
Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedTannic acid Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedTannic acid Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedTannic acid Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedTannic acid Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. |
| Targets&IC50 | CXCR4:～1 nM |
| In vitro | Treatment with Motixafortide induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to Motixafortide undergoes differentiation. Motixafortide induces the apoptosis of AML cells in vitro, which is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. Motixafortide-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways. |
| In vivo | Motixafortide also synergizes with FLT3 inhibitors to induce AML cell death. Importantly, this combined treatment prolongs the survival of tumor-bearing mice and reduces minimal residual disease in vivo. |
| Alias | TF 14016 TFA, T140 TFA, BL-8040 TFA, BKT140 TFA |
| Molecular Weight | 2273.54 |
| Formula | C99H145F4N33O21S2 |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | H2O: 100 mg/mL (46.31 mM), Sonication is recommended. DMSO: 100 mg/mL (46.31 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Motixafortide TFA(664334-36-5,Free) | purchase Motixafortide TFA(664334-36-5,Free) | Motixafortide TFA(664334-36-5,Free) cost | order Motixafortide TFA(664334-36-5,Free) | Motixafortide TFA(664334-36-5,Free) chemical structure | Motixafortide TFA(664334-36-5,Free) in vivo | Motixafortide TFA(664334-36-5,Free) in vitro | Motixafortide TFA(664334-36-5,Free) formula | Motixafortide TFA(664334-36-5,Free) molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.